Japan Thrombosis And Hemostasis Biomarkers Market Size & Outlook

The thrombosis and hemostasis biomarkers market in Japan is expected to reach a projected revenue of US$ 470.2 million by 2030. A compound annual growth rate of 5% is expected of Japan thrombosis and hemostasis biomarkers market from 2023 to 2030.

Revenue, 2022 (US$M)
$319.0
Forecast, 2030 (US$M)
$470.2
CAGR, 2023 - 2030
5%
Report Coverage
Japan

Japan thrombosis and hemostasis biomarkers market, 2018-2030 (US$M)

Japan

Related Markets

Japan thrombosis and hemostasis biomarkers market highlights

  • The Japan thrombosis and hemostasis biomarkers market generated a revenue of USD 319.0 million in 2022 and is expected to reach USD 470.2 million by 2030.
  • The Japan market is expected to grow at a CAGR of 5% from 2023 to 2030.
  • In terms of segment, reagents & consumables was the largest revenue generating product in 2022.
  • Reagents & Consumables is the most lucrative product segment registering the fastest growth during the forecast period.


Thrombosis and hemostasis biomarkers market data book summary

Market revenue in 2022USD 319.0 million
Market revenue in 2030USD 470.2 million
Growth rate5% (CAGR from 2022 to 2030)
Largest segmentReagents & consumables
Fastest growing segmentReagents & Consumables
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAnalyzers, Reagents & Consumables
Key market players worldwideBioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories


Other key industry trends

  • In terms of revenue, Japan accounted for 6.4% of the global thrombosis and hemostasis biomarkers market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China thrombosis and hemostasis biomarkers market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 475.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Thrombosis And Hemostasis Biomarkers Market Scope

Thrombosis and hemostasis biomarkers market segmentation & scope
Analyzers
Reagents & Consumables
Clinical Laboratory Tests
Point-of-Care Tests
D-Dimer
Anti-Thrombin III
Plasminogen
Soluble Fibrin
Selectins
Factor VIII
PT
APTT
Fibrinogen
Others
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others
Hospitals & Clinics
Academic & Research Institutes
Diagnostic Centers
Others

Thrombosis And Hemostasis Biomarkers Market Companies

Name Profile # Employees HQ Website

Japan thrombosis and hemostasis biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.


Reagents & consumables was the largest segment with a revenue share of 65.3% in 2022. Horizon Databook has segmented the Japan thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.


The key driving factors are the surge in demand for diagnostics tests due to the increasing prevalence of chronic diseases. In addition, the country has advanced healthcare infrastructure, increasing awareness of point-of-care testing, and high disposable income.

For instance, according to research published by the National Laboratory of Medicine in 2023, the three major disease burdens in Japan include heart disease, cancer, and cerebrovascular disease. CVDs ranked 4th among the causes of death.

In April 2019, the Japan Pharmaceutical Manufacturers Association, the RIKEN Institute, the National Institute of Health Sciences, the Critical Path Institute's Predictive Safety Testing Consortium (PSTC), and the Japan Society of Toxicology collaborated & organized a workshop on Japan Safety Biomarkers at the RIKEN Institute, Japan.

Reasons to subscribe to Japan thrombosis and hemostasis biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan thrombosis and hemostasis biomarkers market databook

  • Our clientele includes a mix of thrombosis and hemostasis biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Japan thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan thrombosis and hemostasis biomarkers market size, by product, 2018-2030 (US$M)

Japan Thrombosis And Hemostasis Biomarkers Market Outlook Share, 2022 & 2030 (US$M)

Japan thrombosis and hemostasis biomarkers market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more